Angiotensin II Receptor Antagonists: An Emerging New Class of Cardiovascular Therapeutics

Hypertension Research - Clinical and Experimental

Volumn 22, Issue 2, 1999, Pages 147-153

  Timmermans, Pieter B M W M ^a  

^a AMGEN INC   (United States)

Author keywords

Angiotensin II; Angiotensin II receptors; AT1 receptor antagonists; AT1 receptors; Renin angiotensin aldosterone system

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPROSARTAN; IRBESARTAN; LOSARTAN; SAPRISARTAN; TASOSARTAN; TELMISARTAN; VALSARTAN; ZOLASARTAN; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; CARDIOVASCULAR AGENT;

ADRENERGIC SYSTEM; ARTERIAL PRESSURE; CHEMICAL STRUCTURE; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; ANIMAL; DRUG ANTAGONISM; METABOLISM; REVIEW;

ANGIOTENSIN II; ANIMALS; CARDIOVASCULAR AGENTS; HUMANS; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN;

EID: 0032788508     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.22.147     Document Type: Article

References (26)

1. Sealy JE, Laragh JH: The renin-angiotensin-aldosterone system for normal regulation of blood pressure and sodium and potassium homeostasis, in Laragh JH, Brenner B (eds): Hypertension: Pathophysiology, Diagnosis and Management. New York, Raven Press, 1995, pp1763-1796.
2. Pals DT, Masucci FD, Sipos F, Denning GS: -A specific competitive antagonist of the vascular action of angiotensin II. Circ Res 1971; 29: 664-672.
3. Brunner HR, Gavras H, Laragh JH, Keenan R: Angiotensin II blockade in man by sar'-ala8-angiotensin II for understanding and treatment of high blood pressure. Lancet 1973; 2: 1045-1048.
4. Furukawa Y, Kishimoto S, Nishikawa K: Hypotensive imidazole derivatives. U.S. Patent 4,340,598. Issued to Takeda Chemical Industries, Ltd, Osaka, Japan, 1982.
5. Furukawa Y, Kishimoto S, Nishikawa K: Hypotensive imidazole-5-acetice acid derivatives. U.S. Patent 4,355,040. Issued to Takeda Chemical Industries, Ltd, Osaka, Japan, 1982.
6. Chiu AT, Carini DJ, Johnson AL, et al: Nonpeptide angiotensin II receptor antagonists: II. Pharmacology of S-8308. Enr J Plwrmacol 1988; 157: 13-21.
7. Duncia JV, Chiu AT, Carini DJ, et al: The discovery of potent nonpeptide angiotensin II receptor antagonists: a new class of potent antihypertensives. J Med Cliem 1990; 33: 1312-1329.
8. Weinstock J, Keenan RM, Samanen J, et al: l-(Carboxybenzyl)imidazole-5-acrylic acids: potent and selective angiotensin II receptor antagonists. J Med Chem 1991; 34: 1514-1517.
9. Wexler RR, Greenlee WJ, Irvin JD, et al: Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy. J Med Chem 1996; 39: 625-656.
10. de Gasparo M, Husain A, Alexander W, et al: Proposed update of angiotensin receptor nomenclature. Hypertension 1995; 25: 924-927.
11. 11'. Timmermans PBMWM, Wong PC, Chiu AT, et al: Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45: 205-251.
12. Wong PC, Price WA, Chiu AT, et al: Nonpeptide angiotensin II receptor antagonists XI. Pharmacology of EXP3174: an active metabolite of DuP 753, and orally active antihypertensive agent. J Pharmacol Exp Tlier 1990; 255: 211-217.
13. Criscione L, de Gasparo M, Buhlmayer P, Whitebread S, Ramjoue HP, Wood J: Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II ATj-receptor subtype. Br J Pharmacol 1993; 110: 761-771.
14. Cazaubon C, Gougat J, Bousquet F, et al: Pharmacological characterization of SR47436: a new nonpeptide ATi subtype angiotensin II receptor antagonist. J Pharmacol Exp Ther 1993; 265: 826-834.
15. Shibouta Y, Inada Y, Ojima M, et al: Pharmacological profile of the highly potent and long-acting angiotensin II receptor antagonist, CV-11974, and its prodrug TCV-116. J Pharmacol Exp Ther 1993; 266: 114-120.
16. Ellingboe JW, Antane M, Nguyen TT, et al: Pyrido [2,3-d]pyrimidine angiotensin II antagonists. J Med Cliem 1994; 37: 542-550.
17. Lacourciere Y, Pool JL, Svetkey L, et al: A randomized, double-blind, placebo-controlled, parallelgroup, multicenter trial of four doses of tasosartan in patients with essential hypertension. Am J Hypertens 1998; 11: 454-461.
18. Wienen W, Hanel N, van Meel JCA, Narr B, Ries UJ, Entzeroth M: Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. Br J Pharmacol 1993; 110: 245252.
19. Hilditch A, Hunt AAE, Gardner CJ, et al: Cardiovascular effects of GR11789, a novel angiotensin ATi receptor antagonist. Br J Pharmacol 1994; 111: 137144.
20. Judd DB, Dowle MD, Middlemiss D, et al: Bromo-benzofuran-based non-peptide antagonists of angiotensin II: GR138950, a potent antihypertensive agent with high oral bioavailability. J Med Chem 1994; 37: 3108-3120.
21. Gaddum JH, Hameed KA, Hathaway DE, Stephens FF: Quantitative studies of antagonists for 5-hydroxytryptamine. Q J Exp Physiol 1995; 40: 49-74.
22. Rang HP: The kinetics of action of acetylcholine antagonists in smooth muscle. Proc R Soc Land D Biol Sci 1966; 164: 488-510.
23. Kenakin TP: The classification of drugs and drug receptors in isolated tissues. Pharmacol Rev 1984; 36: 165-222.
24. Brunner HR: The new angiotensin II receptor antagonist, irbesartan. Pharmacokinetic and pharmacodynamic considerations. Hypertension 1997; 10: 311S317S.
25. MacFadyen RJ, Reid JL: Angiotensin receptor antagonists as treatment for hypertension. J Hypertens 1994; 12: 1333-1338.
26. Csajka C, Buclin T, Brunner HR, Biollaz J: Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists. Clin Pharmacokinet 1997; 32: 1-29.